<DOC>
	<DOCNO>NCT02927795</DOCNO>
	<brief_summary>This self-controlled study design enrol consent COPD patient treat Spiolto® Respimat® accord approve SmPC . Patients enrol consecutively followed observational period approx . 6 week .</brief_summary>
	<brief_title>OTIVACTO Spain Non Interventional Study</brief_title>
	<detailed_description>Purpose : Study Design :</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Inclusion criterion : 1 . Written inform consent prior participation 2 . Female male patient = &gt; 40 year age 3 . Patients diagnose Chronic Obstructive Pulmonary Disease ( COPD ) require longacting dual bronchodilation ( Longacting muscarinic antagonist ( LAMA ) + Longacting beta2 agonist ( LABA ) ) treatment accord approve Spiolto® Respimat® Summary Product Characteristics ( SmPC ) COPD GOLD guideline recommendation Exclusion criterion : 1 . Patients contraindication accord Spiolto® Respimat® SmPC 2 . Patients treat LABA/LAMA combination ( free fix dose ) previous 6 month 3 . Patients continue Longacting beta2 agonist inhalative corticosteroid ( LABAiCS ) treatment additionally treat Spiolto® Respimat® order avoid double dose longacting beta2 agonist 4 . Patients followup possible enrol site plan study period approx . 6 week 5 . Pregnancy lactation 6 . Patients currently list lung transplantation 7 . Current participation clinical trial noninterventional study drug device</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>